|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim NK, Park YS, Heo DS, Suh C, Kim SY,
Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, et al: A phase III
randomized study of 5-fluorouracil and cisplatin versus
5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil
alone in the treatment of advanced gastric cancer. Cancer.
71:3813–3818. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wöhrer SS, Raderer M and Hejna M:
Palliative chemotherapy for advanced gastric cancer. Ann Oncol.
15:1585–1595. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choi HS, Ha SY, Kim HM, Ahn SM, Kang MS,
Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, et al: The prognostic
effects of tumor infiltrating regulatory T cells and myeloid
derived suppressor cells assessed by multicolor flow cytometry in
gastric cancer patients. Oncotarget. 7:7940–7951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goodman AM, Kato S, Bazhenova L, Patel SP,
Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R:
Tumor mutational burden as an independent predictor of response to
immunotherapy in diverse cancers. Mol Cancer Ther. 16:2598–2608.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Curiel TJ: Tregs and rethinking cancer
immunotherapy. J Clin Invest. 117:1167–1174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DeNardo DG and Coussens LM: Inflammation
and breast cancer. Balancing immune response: Crosstalk between
adaptive and innate immune cells during breast cancer progression.
Breast Cancer Res. 9:2122007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carreras J, Lopez-Guillermo A, Fox BC,
Colomo L, Martinez A, Roncador G, Montserrat E, Campo E and Banham
AH: High numbers of tumor-infiltrating FOXP3-positive regulatory T
cells are associated with improved overall survival in follicular
lymphoma. Blood. 108:2957–2964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH,
Taki-Eldin A and Zheng SS: Selective recruitment of regulatory T
cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor
progression and predicts poor prognosis. PLoS One. 6:e246712011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deng L, Zhang H, Luan Y, Zhang J, Xing Q,
Dong S, Wu X, Liu M and Wang S: Accumulation of foxp3+ T regulatory
cells in draining lymph nodes correlates with disease progression
and immune suppression in colorectal cancer patients. Clin Cancer
Res. 16:4105–4112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Droeser R, Zlobec I, Kilic E, Güth U,
Heberer M, Spagnoli G, Oertli D and Tapia C: Differential pattern
and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor
infiltrating lymphocytes in ductal and lobular breast cancers. BMC
Cancer. 12:1342012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh
DY, Lee SH, Kim JH, Kim DW, Kim TY, et al: Modified FOLFOX-6
chemotherapy in advanced gastric cancer: Results of phase II study
and comprehensive analysis of polymorphisms as a predictive and
prognostic marker. BMC Cancer. 8:1482008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee
MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, de St Groth
Fazekas B, et al: CD127 expression inversely correlates with FoxP3
and suppressive function of human CD4+ T reg cells. J Exp Med.
203:1701–1711. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia
XF, Sun X, Li GG, Hu QD, Fu QH and Liang TB: Hypoxia-induced
epithelial-to-mesenchymal transition in hepatocellular carcinoma
induces an immunosuppressive tumor microenvironment to promote
metastasis. Cancer Res. 76:818–830. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kelley JR and Duggan JM: Gastric cancer
epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shurin GV, Tourkova IL, Kaneno R and
Shurin MR: Chemotherapeutic agents in noncytotoxic concentrations
increase antigen presentation by dendritic cells via an
IL-12-dependent mechanism. J Immunol. 183:137–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liao J, Xiao J, Zhou Y, Liu Z and Wang C:
Effect of transcatheter arterial chemoembolization on cellular
immune function and regulatory T cells in patients with
hepatocellular carcinoma. Mol Med Rep. 12:6065–6071. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shah W, Yan X, Jing L, Zhou Y, Chen H and
Wang Y: A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes
and a high percentage of CD4(+)FOXP3(+) regulatory T cells are
significantly associated with clinical outcome in squamous cell
carcinoma of the cervix. Cell Mol Immunol. 8:59–66. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Solomayer EF, Feuerer M, Bai L, Umansky V,
Beckhove P, Meyberg GC, Bastert G, Schirrmacher V and Diel IJ:
Influence of adjuvant hormone therapy and chemotherapy on the
immune system analysed in the bone marrow of patients with breast
cancer. Clin Cancer Res. 9:174–180. 2003.PubMed/NCBI
|
|
26
|
Kono K, Kawaida H, Takahashi A, Sugai H,
Mimura K, Miyagawa N, Omata H and Fujii H: CD4(+)CD25high
regulatory T cells increase with tumor stage in patients with
gastric and esophageal cancers. Cancer Immunol Immunother.
55:1064–1071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ke X, Wang J, Li L, Chen IH, Wang H and
Yang XF: Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and
tumors are complex. Front Biosci. 13:3986–4001. 2008.PubMed/NCBI
|
|
28
|
Ladoire S, Martin F and Ghiringhelli F:
Prognostic role of FOXP3+ regulatory T cells infiltrating human
carcinomas: The paradox of colorectal cancer. Cancer Immunol
Immunother. 60:909–918. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haas M, Dimmler A, Hohenberger W,
Grabenbauer GG, Niedobitek G and Distel LV: Stromal regulatory
T-cells are associated with a favourable prognosis in gastric
cancer of the cardia. BMC Gastroenterol. 9:652009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gooden MJ, de Bock GH, Leffers N, Daemen T
and Nijman HW: The prognostic influence of tumour-infiltrating
lymphocytes in cancer: A systematic review with meta-analysis. Br J
Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mougiakakos D, Choudhury A, Lladser A,
Kiessling R and Johansson CC: Regulatory T cells in cancer. Adv
Cancer Res. 107:57–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghadjar P, Rubie C, Aebersold DM and
Keilholz U: The chemokine CCL20 and its receptor CCR6 in human
malignancy with focus on colorectal cancer. Int J Cancer.
125:741–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
